Entresto
Novartis Secures Temporary Block on Generic Version of Entresto
Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug
ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023
ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.
Novartis Fails to Block MSN’s Entresto Generic Launch
Novartis, Entresto, MSN Pharmaceuticals, generic drugs, patent infringement, FDA approval
Novartis Intensifies Entresto Defense with FDA Complaint Amid Patent Lawsuits
Novartis, Entresto, FDA complaint, patent lawsuits, pharmaceuticals
Novartis Sues FDA Over Approval of Entresto Generic After Petition Rejection
Novartis, FDA, Entresto, generic drug, lawsuit, patent exclusivity, heart failure medication